Lentiviral human CDCA2 sgRNA gene knockout kit

Lentiviral human CDCA2 sgRNA gene knockout kit

Catalog Number:
CGKK545798FEN
Mfr. No.:
HKO-611512
Price:
$878
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Kit Components: Lentiviral particles or plasmids for a set of three sgRNAs, and a pair of Indel screening PCR primers

          sgRNA lentiviral particle information
          • Functional titer: 1x10^8 TU/ml
          • Titration method: counting puromycin resistant cell clones
          • Purity: In vivo grade
          • Pseudotype: VSVG
          • Storage buffer: LentiShield™ lentivirus storage buffer
          • Storage: condition -80°C
          • Availability: 3-5 weeks

          sgRNA lentiviral plasmid information
          • Promoter for target sgRNA: U6
          • Mammalian selection: puromycin
          • Promoter for mammalian selection gene: EF1a
          • E.coli selection: Amp
          • Storage condition: -20°C
          • Availability: 1-2 weeks

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Human CDCA2
          About Target
          Gene symbol: CDCA2
          Synonyms: PPP1R81 Repo-Man
          Species: HUMAN
          Gene ID: 157313
          Summary: This gene encodes a targeting subunit of the cell-cycle associated protein, protein phosphatase 1, with a role in targeting this protein to chromatin during anaphase. These two proteins comprise a phosphatase complex that is involved in nuclear envelope reformation and regulation of the DNA damage response. The encoded protein may also play a role in cancer progression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015].
          NM numbers targeted (Accession number:Exon:CDS Fragment): NM_152562:8:7 NM_001317906:7:6 NM_001317907:8:7
      • Properties
        • * For Research Use Only.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.